" class="no-js "lang="en-US"> Ypsomed - Medtech Alert
Thursday, March 30, 2023
Ypsomed | Pharmtech Focus

Ypsomed

About Ypsomed

Ypsomed

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1900 employees.

Related Story

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

April 28 2022

Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize […]